Multi-Target Approach for Drug Discovery against Schizophrenia

Files
Self archived version
published versionDate
2018Author(s)
Unique identifier
10.3390/ijms19103105Metadata
Show full item recordMore information
Self-archived article
Citation
Kondej, M. Stepnicki, P. Kaczor, AA. (2018). Multi-Target Approach for Drug Discovery against Schizophrenia. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19 (10) , 3105. 10.3390/ijms19103105.Rights
Licensed under
Abstract
Polypharmacology is nowadays considered an increasingly crucial aspect in discovering new drugs as a number of original single-target drugs have been performing far behind expectations during the last ten years. In this scenario, multi-target drugs are a promising approach against polygenic diseases with complex pathomechanisms such as schizophrenia. Indeed, second generation or atypical antipsychotics target a number of aminergic G protein-coupled receptors (GPCRs) simultaneously. Novel strategies in drug design and discovery against schizophrenia focus on targets beyond the dopaminergic hypothesis of the disease and even beyond the monoamine GPCRs. In particular these approaches concern proteins involved in glutamatergic and cholinergic neurotransmission, challenging the concept of antipsychotic activity without dopamine D2 receptor involvement. Potentially interesting compounds include ligands interacting with glycine modulatory binding pocket on N-methyl-d-aspartate (NMDA) receptors, positive allosteric modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, positive allosteric modulators of metabotropic glutamatergic receptors, agonists and positive allosteric modulators of α7 nicotinic receptors, as well as muscarinic receptor agonists. In this review we discuss classical and novel drug targets for schizophrenia, cover benefits and limitations of current strategies to design multi-target drugs and show examples of multi-target ligands as antipsychotics, including marketed drugs, substances in clinical trials, and other investigational compounds.
Subjects
antipsychotics drug design multi-target drugs polypharmacology schizophreniaLink to the original item
http://dx.doi.org/10.3390/ijms19103105Publisher
MDPI AGCollections
- Terveystieteiden tiedekunta [1330]